Plexxikon, Roche to work together on new class of cancer drugs

10/9/2006 | American City Business Journals

Roche will pay up to $700 million to Calif.-based biotech Plexxikon to create a new early-stage cancer therapy based on the biotech's compound, which attracted a lot of attention. The drug selectively inhibits a genetic mutation, called B-RafV600E kinase, found in more than 70% of malignant melanomas and a large percentage of other cancers and tumor types.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC